How much did DocMorris revenue grow in the 2025 financial year?

DocMorris said external revenue rose by 11.1 per cent to CHF 1,185.8 million in 2025, while revenue increased by 12.4 per cent to CHF 1,124.5 million. The company said this was achieved despite the discontinuation of the Zur Rose brand in Germany at the end of 2024.

How did DocMorris perform in the fourth quarter of 2025?

DocMorris reported fourth-quarter external revenue growth of 15.5 per cent and revenue growth of 16.6 per cent. External Rx revenue increased by 22.3 per cent year on year, while Non-Rx external revenue grew by 14.9 per cent.

How did DocMorris's prescription medicines business perform in 2025?

DocMorris said external Rx revenue grew by 33.2 per cent to CHF 234.8 million in 2025. In the fourth quarter, Rx external revenue grew by 22.3 per cent compared with a strong prior-year quarter and by 6.1 per cent sequentially from the third quarter of 2025.

How did DocMorris's Non-Rx business perform in 2025?

Non-Rx external revenue increased by 7.1 per cent to CHF 887.9 million in 2025. DocMorris said Non-Rx external revenue grew by 14.9 per cent in the fourth quarter, with both OTC and Digital Services contributing to growth.

What drove DocMorris's Digital Services growth in 2025?

DocMorris reported that Digital Services revenue increased by 110 per cent in 2025, including a 124 per cent increase for TeleClinic. Retail Media and Marketplace revenue grew by 88 per cent to CHF 13.6 million, while TeleClinic revenue rose by 124 per cent to CHF 24.9 million.

How many DocMorris customers were active at the end of 2025?

DocMorris said the number of active customers increased from 10.3 million to 11.0 million during 2025. The company said this increase occurred despite the loss of former Zur Rose Germany customers.

How widely has the DocMorris AI assistant been used?

DocMorris said every third app user had already used its AI assistant. CEO Walter Hess described the assistant as a connecting element in the expansion of the company's digital health platform.

How did DocMorris's German and Europe segments perform in 2025?

The Germany segment recorded external revenue growth of 11.7 per cent and revenue growth of 13.1 per cent in 2025. The Europe segment grew by 1.7 per cent, with DocMorris stating that it maintained a consistent focus on profitability.

What did DocMorris management say about the 2025 results?

CEO Walter Hess said DocMorris recorded robust growth in its core online pharmacy business and strong momentum in Digital Services, including telemedicine and retail media. CFO Daniel Wüest said all business areas contributed to the 2025 targets and that development accelerated particularly in the fourth quarter, alongside an increased focus on marketing efficiency for prescription medicines.

What are DocMorris's earnings and breakeven expectations?

DocMorris confirmed the earnings forecast for the 2025 financial year communicated on 10 April 2025 and specified the EBITDA forecast as a range of minus CHF 48 to minus CHF 52 million. The company also confirmed EBITDA breakeven in the course of 2026 and free cash flow breakeven in the course of 2027; these statements are forward-looking and the announcement says actual results may differ because of risks and uncertainties.

Where are DocMorris AG shares listed and what is the ticker?

The shares of DocMorris AG are listed on the SIX Swiss Exchange under securities number 4261528, ISIN CH0042615283 and ticker DOCM.

What does DocMorris do and how does its business operate?

DocMorris AG is a Swiss-based company operating in online pharmacy, telemedicine and marketplace services, with strong brands in Germany and other European countries. Deliveries are mainly made from its highly automated logistics centre in Heerlen, the Netherlands; TeleClinic connects patients with more than 6,000 physicians, and DocMorris operates marketplaces for health and personal care products in Southern Europe.

What are DocMorris's next scheduled reporting dates?

DocMorris's next scheduled event is its 2025 full-year results and outlook 2026 in Zurich or in a hybrid format on 19 March 2026. Its agenda also lists a Q1/2026 trading update on 16 April 2026, the Annual General Meeting in Zurich on 12 May 2026, 2026 half-year results on 19 August 2026 and a Q3/2026 trading update on 15 October 2026.

Home
News Intelligence
DocMorris AG
DocMorris reports 11.1 per cent external revenue growth in 2025

Back to all DocMorris AG press releases

DocMorris AG

SIX:DOCM

DocMorris reports 11.1 per cent external revenue growth in 2025

Published Tuesday, 20 January 2026, 06:00 AM

Get alerts

Plain English summaries when DocMorris AG announces news.

At a glance

Company: DocMorris AG
Listings: SIX:DOCM
Announcement type: Financial results
Published: Tuesday, 20 January 2026, 06:00 AM
Reporting period: 2025 financial year
Source announcement: eqs-news.com

Key figures
Measure	Figure	Period
External revenue	CHF 1,185.8 million	2025 financial year
Revenue	CHF 1,124.5 million	2025 financial year
External Rx revenue	CHF 234.8 million	2025
Non-Rx external revenue	CHF 887.9 million	2025
Retail Media and Marketplace	CHF 13.6 million	2025

Figures are quoted from this announcement and selected automatically.

FAQSIR Generated from this announcement View original release below for safe harbor and regulatory notices

Announcement Summary

DocMorris AG (DOCM) reported 2025 results, including external revenue, which includes consolidated revenue plus online revenue of supplied pharmacies, less consolidated revenue from supplying them.

External revenue: 11.1 per cent to CHF 1,185.8 million; revenue: as much as 12.4 per cent to CHF 1,124.5 million.
Rx external revenue grew 33.2 per cent to CHF 234.8 million; Non-Rx external revenue increased 7.1 per cent to CHF 887.9 million.
In Q4 2025, external revenue grew 15.5 per cent, Rx external revenue 22.3 per cent and Non-Rx external revenue 14.9 per cent.
Active customers rose from 10.6 million to 11.0 million in Q4 2025 and from 10.3 million to 11.0 million for the full year.
Management specified the 2025 EBITDA forecast at minus CHF 48 to minus CHF 52 million.

Management confirms EBITDA breakeven in the course of 2026 and free cash flow breakeven in the course of 2027. All percentages are in local currency.

Investor FAQs

DocMorris announced its 2025 financial-year results, reporting 11.1 per cent growth in external revenue and 12.4 per cent growth in revenue, alongside a strong fourth quarter. It also confirmed its EBITDA and free cash flow breakeven expectations and provided its 2026 reporting agenda.

Source announcement

Company: DocMorris AG
Title: DocMorris achieves 11.1 per cent revenue growth in 2025 – strong fourth quarter
Published: Tuesday, 20 January 2026, 06:00 AM
Source site: eqs-news.com

Read the source announcement on eqs-news.com

FAQSIR's summary and investor FAQs are generated by AI from the text of this announcement alone, without information from other sources.

Figures, forecasts and other claims are the announcement's, not FAQSIR's. FAQSIR does not independently verify them.

Read the original press release

Full text as published, unedited.

Loading the original release…

Important Notice And Disclaimer

This article was generated by an artificial intelligence system from an announcement published by the issuer. It has not been independently researched, verified, or edited by a journalist, and no person holds editorial responsibility for its wording.

The issuer named in this article has not paid for this page and has no commercial relationship with its publisher. This is an unpaid evaluation preview produced from announcements the issuer published publicly, and it is not independent editorial coverage.

This article does not provide any financial advice and is not a recommendation to deal in any securities or product. Investments may fall in value and an investor may lose some or all of their investment. Past performance is not an indicator of future performance.

Ask about this announcement

Answers drawn only from this announcement

Reading the announcement…